ESTUDO DA EFICÁCIA DE UM NOVO PRODUTO À BASE DE ÁLCOOL GEL UTILIZADO NA ANTI-SEPSIA EM UM SERVIÇO DE NEFROLOGIA

The healthcare is always challenged by medical assistance related infections, which generate higher rates of morbidity and mortality as well as unnecessary costs. The ethyl alcohol has been recognized for its antimicrobial activity against most microorganisms that cause infections in the healthcare setting. The major disadvantage of alcohol for skin antisepsis is its drying effect. This study was performed at the Clínica Renal in Santa Maria, RS, with the objective of testing a new biogel product, alcohol gel, to evaluate its efficacy as a hospital antiseptic, eliminating the necessity of washing the arm of the arterial-venous fistula (AVF) of the patient submitted to hemodialysis. The methodology used was the “Randomized Clinical Trial” and was carried out in eleven patients submitted to hemodialysis in January and February 2005. The study included the culture of skin before and after the antiseptic proceedings, using alcohol 70% and the Biogel® product, and the evaluation of the bacteriostatic and bactericide of the Biogel against gram-negative and gram-positive bacteria. The results showed that the performance of both antiseptics methods was the same, presenting an antiseptic activity of 72.7% and giving the Biogel® bactericide activity against the tested microorganisms.A atenção à saúde é permanentemente desafiada pelas infecções relacionadas aos procedimentos assistenciais, que resultam no aumento da morbidade, mortalidade e custos operacionais. O álcool etílico possui propriedades antimicrobianas reconhecidas, capazes de eliminar os microrganismos mais freqüentemente envolvidos nas infecções em serviços de saúde. A maior desvantagem do álcool para a anti-sepsia da pele é seu efeito ressecante. Este estudo foi realizado na Clínica Renal de Santa Maria, RS, com o objetivo de avaliar a eficácia antiséptica de um novo produto à base de álcool gel (Biogel®), na tentativa de eliminar a necessidade da lavagem com água e sabão do braço com a Fístula Artério Venosa (FAV), dos pacientes submetidos à hemodiálise. A metodologia utilizada foi um estudo experimental do tipo “Ensaio Clínico Randomizado” realizado com onze pacientes ambulatoriais submetidos à hemodiálise nos meses de janeiro a fevereiro de 2005. Foi efetuada cultura da pele anterior e posterior ao procedimento da anti-sepsia, utilizando o álcool 70 % e o produto Biogel®, e avaliação da atividade antibacteriana do Biogel®, frente à bactérias gram-positivas e gram-negativas correspondentes à cepas nosocomiais isoladas de pacientes atendidos no Hospital Universitário de Santa Maria (HUSM). Os resultados mostraram igual desempenho dos dois métodos de anti-sepsia, apresentando uma atividade anti-séptica de 72,7%, e conferindo também atividade bactericida ao Biogel®, frente às cepas testadas

Triazenes and antibacterial activity

Quinze compostos triazenos foram estudados quanto à atividade antibacteriana pela metodologia de microdiluição em caldo. A Concentração Inibitória Mínima (CIM) e a Concentração Bactericida Mínima (CBM) foram pesquisadas frente a três bactérias padrão (E. coli ATCC 25922, Staphylococcus aureus ATCC 25923, Pseudomonas aeruginosa ATCC 27853) e frente a cepas hospitalares (Acinetobacter baumannii, Acinetobacter lwoffii, Ralstonia pickettii, Bordetella bronchiseptica, Micrococcus sp., Enterococcus sp., Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Bacillus cereus, Corynebacterium sp., Rhodococcus sp., Salmonella sp., Serratia marcescens, Morganella morganii, Enterobacter cloacae, Shigella flexneri, Shigella sonnei, Shigella sp., Klebsiella pneumoniae, ESBL Klebsiella oxytoca 14, ESBL Klebsiella pneumoniae 23, ESBL Klebsiella pneumoniae 24, ESBL Klebsiella pneumoniae 25, ESBL Escherichia coli 26, ESBL Klebsiella pneumoniae 27, ESBL Klebsiella pneumoniae 31, ESBL Escherichia coli 32, ESBL Klebsiella pneumoniae 37 e ESBL Escherichia coli 38). A maior atividade foi evidenciada para o composto 1-metil-3-(p-carboxifenil)triazeno 1-óxido (2) contra Streptococcus agalactiae (CIM =16 µg/mL e CBM = 32 µg/mL). Os compostos 1-fenil-3-(4-nitrofenil)triazeno-1-óxido (9), 1-(4-nitrofenil)-3-(4-carboxifenil)triazeno (10) e 1-(4-acetilaminofenil)-3-(4-carboxifenil)triazeno (11) apresentaram CIMs de 32 a 64 µg/mL frente a S. edipermidis, S. saprophyticus, Corynebacterium sp. e E. cloacae. Os compostos 1-metil-3-feniltriazeno-1-óxido (1) , bis-1,3-(4-acetiloxima)triazeno (3), bis-1,3 (4-acetilfenil)triazeno (4), 1-(2-fluorfenil)-3-(4-acetilfenil)triazeno (5), 1,3-(3-hidroxi-difeniltriazenido)(piridil)(bis-oxo-vanádio) (12), 1-(3-nitrofenil)-3-feniltriazeno (14), 1-(4-nitrofenil)-3-benziltriazeno (15) apresentaram CIM = 128 µg/mL frente a S. aureus ATCC 25923, P. aeruginosa ATCC 27853, A. lwoffii, Micrococcus sp., S. epidermidis, S. saprophyticus, Corynebacterirum sp., E. cloacae, S. flenneri e S. sonnei. Os compostos 1-fenil-3-(4-acetilfenil)triazeno (6), 1,3-bis-(4-etoxicarbonilfenil) triazeno (7) e 3-(4-carboxilatofenil)-1-metiltriazeno 1-óxido de potássio tetraidratado (13) apresentaram CIMs iguais ou maiores que 128 µg/mL. Estes resultados demonstraram a potencial atividade biológica destes compostos contra bactérias Gram-positivas e Gram-negativas.Fifteen triazenes compounds were studied concerning their antibacterial activity by broth microdilution method. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) was determined with E. coli ATCC 25922, Staphylococcus aureus ATCC 25923, Pseudomonas aeruginosa ATCC 27853, Acinetobacter baumannii, Acinetobacter lwoffii, Ralstonia pickettii, Bordetella bronchiseptica, Micrococcus sp., Enterococcus sp., Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Bacillus cereus, Corynebacterium sp., Rhodococcus sp., Salmonella sp., Serratia marcescens, Morganella morganii, Enterobacter cloacae, Shigella flexneri, Shigella sonnei, Shigella sp., Klebsiella pneumoniae, ESBL Klebsiella oxytoca 14, ESBL Klebsiella pneumoniae 23, ESBL Klebsiella pneumoniae 24, ESBL Klebsiella pneumoniae 25, ESBL Escherichia coli 26, ESBL Klebsiella pneumoniae 27, ESBL Klebsiella pneumoniae 31, ESBL Escherichia coli 32, ESBL Klebsiella pneumoniae 37 e ESBL Escherichia coli 38. The highest effect was evidenced by the compound 1-methyl-3-(p-carboxyphenyl)triazene 1-oxide (2) against Streptococcus agalactiae (MIC = 16 µg/mL and MBC = 32 µg/mL). The compounds 1-phenyl-3-(4-nitrophenyl)triazene-1-oxide (9), 1-(4-nitrophenyl)-3-(4-carboxyphenyl)triazene (10) e 1-(4-acethyl amine phenyl)-3-(4-carboxyphenyl)triazene (11) presented MIC between 32 and 64 µg/mL against S. edipermidis, S. saprophyticus, Rhodococcus sp. and E. cloacae. The compounds 1-methyl-3-phenyltriazene-1-oxide (1) , bis-1,3-(4-acethyl oxime)triazene (3), bis-1,3 (4-acethyl phenyl)triazene (4), 1-(2-fluorophenyl)-3-(4-acethylphenyl)triazene (5), 1,3-(3-hydroxy-diphenyltriazenide)(piridil)(bis-oxo-vanadium) (12), 1-(3-nitrophenyl)-3-phenyltriazene (14), 1-(4-nitrophenyl)-3-benzyltriazene (15) presented MIC of the 128 µg/mL against S. aureus ATCC 25923, P. aeruginosa ATCC 27853, A. lwoffii, Micrococcus sp., S. epidermidis, S. saprophyticus, Corynebacterirum sp., E. cloacae, S. flenneri e S. sonnei. The compounds 1-phenyl-3-(4-acethylphenyl)triazene (6), 1,3-bis-(4-ethoxycarbonylphenyl) triazene (7), and 3-(4-carboxylatephenyl)-1-methyltriazene 1-oxide of potassium tetrahydrate (13) presented MICs equals or highest than 128 µg/mL. The results have demonstrated the potential biological activity of these compounds against Gram-positive and Gram-negative bacteria

IN VITRO

Bacterial resistance to antibacterial agents is currently a major concern. We report the synthesis, in vitro antibacterial activity and toxicity toward Artemia salina of six diaryltriazene compounds bearing different substituent groups. Minimal Inhibitory Concentration (MIC) and Minimal Bactericidal Concentration (MBC) values against standard strains (ATCC) and clinical isolates (including ESBL, MBL and AmpC strains) were good to very good, in the range 8 to 128 mg mL-1. Results suggest that hydroxyl, 4-carboxyl and 4-phenyldiazenil groups attached to the diaryltriazenes provide enhanced activity. Toxicity results showed very low LC50 values for three compounds (10-fold lower than DTIC)